Category: Insulin

Novo Nordisk Logo

Hypoglycemia Common Among Type 2 Diabetes Patients Treated with Insulin

According to the GAPP2™ (Global Attitudes of Patients and Physicians) survey, funded by Novo Nordisk and presented today at the Annual Meeting of the European Association for the Study of Diabetes (EASD), four out of five (80%) people with type 2 diabetes have experienced self-treated hypoglycemia...
0 Shares
Novo Nordisk Logo

Novo Nordisk’s Ultra-Long Acting Insulin, Tresiba, Approved in Japan

The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk's ultra-long acting insulin, insulin degludec, for treatment of diabetes. Insulin degludec, marketed globally under the name Tresiba, is a new generation of once-daily basal insulin, which has been discovered and developed by Novo Nordisk.
0 Shares
Biodel logo

Biodel Initiates a Phase 2 Study of Ultra-Rapid-Acting Insulin

Biodel has initiated a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123. The study is designed to assess the clinical impact of the ultra-rapid absorption profile of BIOD-123 relative to currently marketed mealtime insulin analogs. In April 2012, Biodel announced positive top-line results from a Phase 1 clinical trial of BIOD-123, which demonstrated that the formulation had a more rapid absorption...
0 Shares
Halozyme_logo

Positive Results for Halozyme’s Prandial Insulin Formulations

Halozyme Therapeutics announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes. The study met its primary endpoint of A1C non-inferiority. Further...
0 Shares
Lilly - Boehringer - logo

Lilly’s Investigational Basal Insulin Shows Better Results than Lantus

Newly Presented results from two Phase II studies of Eli Lilly and Boehringer Ingelheim's investigational novel basal insulin analog, LY2605541, show that that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than Lantus (insulin glargine) in patients...
0 Shares
sanofi-logo

Lantus Does Not Increase Cancer Risk, New Studies Show

Sanofi has announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California...
0 Shares
biodel_logo

Biodel Obtains Technologies for Development of Glucagon Formulations

Biodel Inc. has partnered with Aegis Therapeutics, LLC (Aegis) and has obtained exclusive worldwide license to Aegis' proprietary ProTek and Intravail technologies for the development and commercialization of pharmaceutical formulations of glucagon...
0 Shares